세계 정밀의료 시장 규모는 2024-2031년 예측 기간 동안 9.73%의 CAGR로 2023년 516억 9,000만 달러에서 2031년 1,086억 1,000만 달러로 확대될 것으로 예측됩니다. 세계 정밀의료 시장을 형성하는 요인은 다양합니다. 여기에는 연구 중심성 증가, 만성질환에 대한 정밀의료의 광범위한 활용, 암 치료의 혁신, 진단에 대한 활용 증가, 정밀의료 플랫폼의 인기 증가 등이 포함됩니다.
연구에 대한 관심이 높아지면서 정밀의료 세계 시장 점유율에 큰 영향을 미치고 있습니다. 정밀의료에 필수적인 유전자 데이터를 생성하기 위한 게놈 센터에 대한 자금 지원은 정밀의료 이니셔티브(PMI)와 같은 프로그램이 혁신을 촉진하는 한 가지 방법입니다. 이 연구 분야는 맞춤형 치료 전략을 개선할 수 있습니다. 정밀의료가 암 치료에 혁명을 일으키고 있는 것도 세계 정밀의료 시장의 성장을 촉진하고 있습니다. 정밀의료는 조기 발견과 치료 효과를 높입니다. 유전자 시퀀싱 및 개인화 진단과 같은 첨단 기술의 사용을 통해 진단에서 정밀 의료에 대한 수요가 증가함에 따라 질병의 식별 및 관리가 개선되고 있습니다.
세계 정밀의료 시장 규모는 만성질환 치료에 정밀의료가 광범위하게 활용되면서 영향을 받고 있습니다. 정밀의료는 각 환자의 고유한 유전자 프로필과 질병 특성에 맞게 치료법을 맞춤화함으로써 만성질환 치료 제공 방식에 혁명을 일으키고 있습니다. 이러한 개별화 접근 방식은 치료 효과를 높입니다. 정밀의료는 보다 정밀하고 효과적인 치료법을 개발하는 데 도움이 되기 때문에 암 치료에도 널리 사용되고 있습니다. 이 방법은 환자의 결과와 치료 모두 개선될 수 있습니다. 정밀의료 플랫폼의 수용 확대는 세계 정밀의료 시장 성장에 큰 영향을 미치고 있습니다. 정밀의료 플랫폼은 조기 개입과 잠재적으로 생명을 구할 수 있는 조치를 가능하게 하고, 반응적 의료에서 예방적 의료로 초점을 전환합니다. 이러한 플랫폼은 환자의 유전적 구성, 생활습관 및 주변 환경에 따라 개별화된 치료 요법을 개발할 수 있게함으로써 환자의 결과를 개선할 수 있습니다. 또한 시행착오의 필요성을 줄이고 비용 효율적인 치료를 촉진하며 임상 결과를 개선할 수 있습니다.
이 보고서는 세계 정밀의료 시장을 조사하여 시장 개요와 함께 용도별, 용도별, 기술별, 최종사용자별, 지역별 동향, 시장 진입 기업 개요 등을 제공합니다.
The global precision medicine market is projected to witness a CAGR of 9.73% during the forecast period 2024-2031, growing from USD 51.69 billion in 2023 to USD 108.61 billion in 2031. Various factors shape the global precision medicine market. These include an increased focus on research, extensive use of precision medicine in chronic diseases, revolutionizing treatment for cancer, increasing use in diagnostics, and growing popularity of precision medicine platforms.
The increased focus on research has a significant impact on the global precision medicine market share. Funding genome centers to produce essential genetic data for precision medicine is one way that programs like the Precision Medicine Initiative (PMI) stimulate innovation. This area of study improves customized treatment strategies. The way precision medicine is revolutionizing cancer treatment is also substantially bolstering the growth of the global precision medicine market. Precision medicine enhances the effectiveness of early detection and therapy. Through the use of cutting-edge technology like gene sequencing and personalized diagnostics, the growing demand for precision medicine in diagnostics is improving disease identification and management.
The global precision medicine market size has also been affected by the extensive use of precision medicine in treating chronic diseases. By customizing treatments to each patient's unique genetic profile and illness characteristics, precision medicine is revolutionizing the way chronic disease care is provided. This individualized approach enhances the results of treatment. Precision medicine is extensively used in treating cancer as it helps in developing more precise and effective therapeutics. Both patient outcomes and care are improved by this method. The growing acceptance of precision medicine platforms greatly impacts the global precision medicine market growth. Precision medicine platforms enable early interventions and potentially life-saving procedures by shifting the focus from reactive to preventative healthcare. By allowing the creation of individualized treatment regimens based on a patient's genetic composition, way of life, and surroundings, these platforms improve patient outcomes. They also reduce the need for trial-and-error methods, promote cost-effective care, and enhance clinical results.
Frederick Health, a top healthcare organization with its main office located in Frederick County, Maryland, decided to improve its precision medicine program on February 27, 2024, by integrating GenomOncology's Precision Oncology Platform with the industry-leading MEDITECH Expanse Genomics solution.
Increased Focus on Precision Medicine Research
One of the major global precision medicine market trends is the heightened emphasis on precision medicine research. Research projects like the Precision Medicine Initiative (PMI) provide funding to genome centers so they can produce the vital genomic data needed for customized therapeutic strategies. The creation of individualized treatment programs based on a patient's genetic composition, way of life, and surroundings is made possible by this study area, improving patient results. Important breakthroughs in precision medicine, such as single nucleotide polymorphism and microarray/biochips, are driving advances in cancer biologics and revolutionizing therapeutic approaches, which, in turn, is fueling the global precision medicine market growth. The human genome is still being studied, and this research has the potential to change medical practices and enhance patient care. This is where precision medicine is headed.
On February 13, 2024, the University of Sydney in Australia announced a five-year research agreement with Bruker, a world-renowned maker of high-performance scientific instruments, marking a significant advancement in precision medicine. As part of the collaboration, the University will get two Bruker atomic force microscopes to expand its top-notch research infrastructure. This month, the next generation of microscopes will be installed.
Extensive Use of Precision Medicine in Chronic Diseases
One major factor fueling the growth of the global precision medicine market is the widespread application of precision medicine in the treatment of chronic illnesses. By customizing medicines to each patient's unique genetic profile and illness characteristics, precision medicine is revolutionizing treatment approaches for chronic diseases, such as cancer, cardiovascular disease, and neurological disorders. Improved patient outcomes result from this tailored strategy, which also reduces side effects and increases therapeutic efficacy. The aging population and the increasing incidence of chronic diseases globally are driving the need for precision medicine in diagnostics and treatments, which is propelling the growth of the global precision medicine market. The focus of healthcare is shifting from reactive to preventative strategies for better health outcomes, owing to precision medicine's capacity to identify patients at higher risk of developing specific diseases early on, enabling preventive actions.
In June 2023, the Oxford Endometriosis Gene (OXEGENE) dataset was licensed to PrecisionLife, a premier biotech company that is advancing precision medicine in complex chronic diseases. This enabled PrecisionLife to create novel, individualized medicines for endometriosis patients. Ten percent of women worldwide are affected with endometriosis, a chronic illness that causes excruciating agony and infertility.
Revolutionizing Treatment for Cancer
One of the main factors propelling the growth of the global precision medicine market is the widespread application of precision medicine in cancer therapy. As more oncologists use precision medicine to treat patients based on their genetic profiles, the market is growing because of the increased availability of more focused and efficient cancer medicines. When compared to normal treatments, precision medicine's customized medicines based on each patient's unique genetic profile and disease features have the potential to shorten side effects and speed up recovery. Precision medicine advancements, including molecular testing in cancer care, allow doctors to choose treatments that maximize beneficial side effects and increase survival rates, which propels market growth.
To boost Moderna's cancer ambitions, the precision medicine startup Caris Life Science, which focuses on artificial intelligence, collaborated with Moderna in October 2023. Moderna's cancer pipeline will be advanced by using Caris's deidentified data library as part of its multiyear agreement. The collaboration will also concentrate on identifying novel biomarkers, improving clinical trial design, and characterizing resistance mechanisms.
Increasing Use in Diagnostics
These days, image-based diagnostics make extensive use of precision medicine, which is greatly fueling the expansion of the global precision medicine market. By considering each patient's distinct genetic and molecular composition, way of life, and environmental influences, this method tailors illness prevention and therapy. By choosing and implementing the best diagnosis and treatment options for each patient, precision medicine in clinical practice seeks to minimize iatrogenic harm, medical costs, and patient benefits. The use of biomarkers is fundamental to customized diagnosis and treatment. Customized diagnosis and treatment are integrated with image-based invasive intervention.
In January 2024, Merck KGaA, a multinational science and technology firm based in Germany, and Quibim, a business that turns imaging data into actionable forecasts of cancer development and therapy responses, collaborated to develop the next generation of image-based diagnostics for precision medicine.
North America Dominating the Market
With a significant revenue share of more than 40%, North America dominates the global precision medicine market. The region's large investments in precision medicine projects, especially in oncology-targeted treatments, and the rising demand for precision medicine applications are acknowledged as contributing causes to this leadership position. The existence of significant industry leaders reinforces North America's predominant position in the advancement and use of precision medicine. The area also leads the precision medicine sector in terms of innovation and growth because of its substantial R&D investments and sophisticated hospital infrastructure.
The US state of California will have a precision medicine center thanks to cooperation announced in January 2024 by Bios Health, a leader in the development of AI-driven precision medicine for the nervous system, with the city of Bakersfield and the Kern Venture Group. Using adaptive dosage technology from BIOS, the facility will function as a center for neurological clinical studies and research and development (R&D).
Future Market Scenario (2024 - 2031F)
To provide patients with personalized medication, health systems are combining several platforms, such as artificial intelligence and data analytics software. Such ventures are driving the growth of the global precision medicine market.
The global precision medicine market will advance with the development of novel diagnostics and biomarkers since doctors will be better equipped to find targeted treatments for a wider range of causes.
In the future, the use of immunotherapy and new diagnostic and bioinformatics tools will propel the expansion of the global precision medicine market.
The growing emphasis on molecular testing to enhance prognosis, therapeutic decision-making, and outcomes will drive growth in the global precision medicine market.
Key Players Landscape and Outlook
Leading businesses in the global precision medicine market are aggressively forming alliances to improve their skills and methodologies. The growth of the market is being propelled by partnerships, which facilitate the diversification of product offerings, augment R&D endeavors, and stimulate technological innovation in precision medicine. By facilitating the sharing of knowledge, resources, and technology, these strategic alliances help to build increasingly sophisticated precision medicine solutions. Companies can improve their market position, quicken the pace of product development, and successfully meet changing healthcare demands by utilizing partnerships.
For instance, on February 27, 2024, Owkin, a biotech company that advances personalized medicine by fusing human and AI tools, announced a partnership with Amazon Web Services (AWS) to transform drug discovery, accelerate clinical trials, and create AI-driven diagnostics. Through this agreement, Owkin's data handling will be improved, operational efficiency will be maximized, and research into precision medicine will be advanced by utilizing AWS's vast global infrastructure and cloud capabilities.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.